Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CheckMate 511: Nivolumab and ipilimumab dosing in melanoma
NCT02714218Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2016
- Primary completion
- Apr 2017
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 3 trial of nivolumab, ipilimumab in melanoma, sponsored by Bristol Myers Squibb. Started Apr 2016; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02714218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02714218.